Soluble C-Type Lectin-Like Receptor 2 Elevation in Patients with Acute Cerebral Infarction.

acute cerebral infarction (ACI) atherosclerotic ACI cardioembolic ACI platelet activation sCLEC-2

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
30 Jul 2021
Historique:
received: 03 07 2021
revised: 28 07 2021
accepted: 28 07 2021
entrez: 7 8 2021
pubmed: 8 8 2021
medline: 8 8 2021
Statut: epublish

Résumé

Acute cerebral infarction (ACI) includes cardiogenic ACI treated with anticoagulants and atherosclerotic ACI treated with antiplatelet agents. The differential diagnosis between cardiogenic and atherosclerotic ACI is still difficult. The plasma sCLEC-2 and D-dimer levels were measured using the STACIA system. The plasma sCLEC-2 level was significantly high in patients with ACI, especially those in patients with atherosclerotic or lacunar ACI, and plasma D-dimer levels were significantly high in patients with cardioembolic ACI. The plasma levels of sCLEC-2 and the sCLEC-2/D-dimer ratios in patients with atherosclerotic or lacunar ACI were significantly higher than those in patients with cardioembolic ACI. The plasma D-dimer levels in patients with atherosclerotic or lacunar ACI were significantly lower than those in patients with cardioembolic ACI. The plasma levels of sCLEC-2 and the sCLEC-2/D-dimer ratios were significantly higher in patients with atherosclerotic or lacunar ACI or acute myocardial infarction in comparison to patients with cardioembolic ACI or those with deep vein thrombosis. Using both the plasma sCLEC-2 and D-dimer levels may be useful for the diagnosis of ACI, and differentiating between atherosclerotic and cardioembolic ACI.

Sections du résumé

BACKGROUND BACKGROUND
Acute cerebral infarction (ACI) includes cardiogenic ACI treated with anticoagulants and atherosclerotic ACI treated with antiplatelet agents. The differential diagnosis between cardiogenic and atherosclerotic ACI is still difficult.
MATERIALS AND METHODS METHODS
The plasma sCLEC-2 and D-dimer levels were measured using the STACIA system.
RESULTS RESULTS
The plasma sCLEC-2 level was significantly high in patients with ACI, especially those in patients with atherosclerotic or lacunar ACI, and plasma D-dimer levels were significantly high in patients with cardioembolic ACI. The plasma levels of sCLEC-2 and the sCLEC-2/D-dimer ratios in patients with atherosclerotic or lacunar ACI were significantly higher than those in patients with cardioembolic ACI. The plasma D-dimer levels in patients with atherosclerotic or lacunar ACI were significantly lower than those in patients with cardioembolic ACI. The plasma levels of sCLEC-2 and the sCLEC-2/D-dimer ratios were significantly higher in patients with atherosclerotic or lacunar ACI or acute myocardial infarction in comparison to patients with cardioembolic ACI or those with deep vein thrombosis.
CONCLUSION CONCLUSIONS
Using both the plasma sCLEC-2 and D-dimer levels may be useful for the diagnosis of ACI, and differentiating between atherosclerotic and cardioembolic ACI.

Identifiants

pubmed: 34362190
pii: jcm10153408
doi: 10.3390/jcm10153408
pmc: PMC8348423
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Japanese Ministry of Health, Labor and Welfare
ID : 21FC1008

Références

Int J Cardiovasc Imaging. 2020 Nov;36(11):2107-2113
pubmed: 32681317
Thromb J. 2021 Feb 25;19(1):12
pubmed: 33632246
Platelets. 2015;26(8):711-9
pubmed: 25856065
Int J Hematol. 2019 Sep;110(3):285-294
pubmed: 31165998
Blood. 2006 Jan 15;107(2):542-9
pubmed: 16174766
Thromb Haemost. 2019 Aug;119(8):1274-1282
pubmed: 31254975
J Thromb Haemost. 2017 Feb;15(2):219-229
pubmed: 27960039
Stroke. 2018 Dec 7;:STROKEAHA118022563
pubmed: 30580704
Thromb Res. 2019 Jun;178:54-58
pubmed: 30978634
Duodecim. ;132(18):1625-33
pubmed: 29188940
Blood. 2018 Sep 13;132(11):1167-1179
pubmed: 29853539
Eur J Clin Invest. 2021 May;51(5):e13467
pubmed: 33259635
Stroke. 2020 Dec;51(12):3504-3513
pubmed: 33198608
BMJ. 2020 Feb 13;368:l6983
pubmed: 32054610
Hamostaseologie. 2020 Feb;40(1):22-30
pubmed: 31648355
J Am Heart Assoc. 2020 Jun 16;9(12):e016299
pubmed: 32476573
J Am Coll Cardiol. 2017 Nov 7;70(19):2411-2420
pubmed: 29096812
Front Med. 2020 Feb;14(1):81-90
pubmed: 31280468

Auteurs

Akisato Nishigaki (A)

Department of Neurology, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Yuhuko Ichikawa (Y)

Department of Central Laboratory, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Minoru Ezaki (M)

Department of Central Laboratory, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Akitaka Yamamoto (A)

Department of Emergency and Critical Care Center, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Kenji Suzuki (K)

Department of Neurology, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Kei Tachibana (K)

Department of Neurology, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Toshitaka Kamon (T)

Department of Neurology, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Shotaro Horie (S)

Department of Neurology, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Jun Masuda (J)

Department of Cardiovascular Medicine, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Katsutoshi Makino (K)

Department of Cardiovascular Medicine, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Katsuya Shiraki (K)

Department of Laboratory and General Medicine, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Hideto Shimpo (H)

Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Motomu Shimaoka (M)

Department of Molecular Pathobiology and Cell Adhesion Biology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.

Katsue Suzuki-Inoue (K)

Department of Clinical and Laboratory Medicine, University of Yamanashi, Yamanashi 409-3898, Japan.

Hideo Wada (H)

Department of Laboratory and General Medicine, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Japan.

Classifications MeSH